Đang chuẩn bị liên kết để tải về tài liệu:
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Due to economic constraints, cancer therapies are under close scrutiny by clinicians, pharmacists and payers alike. There is no published pharmacoeconomic evidence guiding the choice of first-line therapy for advanced renal cell carcinoma (RCC) in the Spanish setting. |

TÀI LIỆU LIÊN QUAN

Impact of budget deficit on growth: A case study of Vietnam

Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: A budget impact analysis

Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model

Economic evaluation of the breast cancer screening programme in the Basque Country: Retrospective cost-effectiveness and budget impact analysis

Return-to-work intervention for cancer survivors: Budget impact and allocation of costs and returns in the Netherlands and six major EU-countries

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

An investigation into the impact of information on stock price volatilities in Vietnam

Nonlinear effects of oil prices on inflation, growth, budget deficit, and unemployment

Impact of budget deficit on growth - a case study of Southeast Asian countries

Impact of trade balance on state budget deficit: International experience and lessons for Vietnam